HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers

AIDS Research and Human Retroviruses

Volumn 17, Issue 12, 2001, Pages 1175-1189

  Gorse, G J ^a   Patel, G B ^a   Belshe, R B ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIVE VACCINE; PLACEBO; PROTEINASE; RECOMBINANT GLYCOPROTEIN GP 120; RGP 120; UNCLASSIFIED DRUG; VCP 205; VCP205 VACCINE; VIRUS GLYCOPROTEIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION RISK; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MEMORY CELL; MULTICENTER STUDY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL; VIRUS ENVELOPE; VIRUS TYPING;

AIDS VACCINES; AVIPOXVIRUS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0034837872     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201316912781     Document Type: Article

References (59)

1. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
2. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo
3. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
4. gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS
5. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection
6. Quantitation of HIV-1-specific cytotoxic T lymphocytes plasma load of viral RNA
7. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
8. Characterization of HIV-1-specific T-helper cells in acute and chronic infection
9. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
10. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
11. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
12. H2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival
13. Cytokine patterns during the progression to AIDS
14. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
15. The Th1-Th2 hypothesis of HIV infection: New insights
16. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry
17. SF-2 recombinant gp120, or both vaccines in seronegative adults
18. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag and pro in combination with rgp120
19. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with SF-2 rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
20. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
21. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
22. SF-2 recombinant gp120
23. MN recombinant gp160 vaccine by dose and schedule of administration
24. MN recombinant glycoprotein 120 vaccine
25. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine
26. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers
27. Detection of intracellular antigen-specific cytokines in human T cell populations
28. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules
29. IIIB rgp120 subunit vaccine
30. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
31. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients
32. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160
33. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120, a randomized, double-blind trial
34. Isolation of mononuclear cells and granulocytes from human blood
35. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses
36. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp)
37. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses
38. Monoclonal antibody and enzymatic profiles of human malignant T lymphoid cells and derived cell lines
39. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
40. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine
41. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
42. A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted by rgp120
43. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
44. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization and quantitation
45. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
46. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine
47. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes
48. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine
49. Recombinant gp160 vaccination schedule and MHC HLA types as factors influencing cellular responses to HIV-1 envelope glycoprotein
50. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
51. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: In vitro quantitation of effector cell populations with p17 and p24 specificities
52. High frequency of gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection
53. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
54. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
55. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
56. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
57. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
58. Cross-clade cytotoxic T cell response to HIV-1 proteins among HLA disparate North Americans and Thais
59. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines